Key History
2023
Nov.
MOU with KINE SCIENCES
Apr.
Obtained governmental research funding for the development of CB-derived Treg cell therapeutics for acquired Aplastic Anemia
Mar.
MOU with Hanyang University Institute for Rheumatology Research
2022
Nov.
Patent Application (Enhanced regulatory T cells and method of manufacturing thereof)
Apr.
Certification of Enterprise Institute (Ministry of Science and ICT)
Feb.
Established R&D Center for Cellular Immunotherapy
2021
Nov.
Obtained Certificate of Venture Business
Oct.
Secured Pre-Series A funding of 4.5 billion won
May.
Initiated non-clinical R&D in GvHD and Aplastic Anemia
Apr.
Established IMMUNIQUE, Inc. with capital investment of 3 billion won from its parent company, MEDI-POST
Secured angel investment of 1.5 billion won